Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Pathology & Oncology Research
Erschienen in: Pathology & Oncology Research 3/2014

01.07.2014 | Research

Prognostic Significance of Cyclin D1 and E-cadherin Expression in Laryngeal Squamous Cell Carcinoma

verfasst von: Rehab Allah Ahmed, Abd El-Aty Shawky, Rasha Hamdy Hamed

Erschienen in: Pathology & Oncology Research | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Cyclin D1 and E-cadherin are important factors in the progression and metastasis of cancers. Their role in laryngeal carcinoma has been studied with conflicting results. To define the frequency of cyclin D1 and E-cadherin expression and its correlation with both the clinicopathological characteristics and prognosis of patients with laryngeal squamous cell carcinoma (LSCC). Tumor tissue samples from 75 patients with laryngeal squamous cell carcinoma were examined for cyclin D1 and E-cadherin expression by immunohistochemistry. The relationship between the expression of both molecules and the age and sex of the patient, tumor site, tumor differentiation, lymph node metastasis, tumor invasiveness, TNM stages, tumor recurrence and overall survival was analyzed. Cyclin D1 was found to be a significant independent prognostic factor of lymph node metastasis (p = 0.000). The multivariate analysis revealed that cyclin D1 and E-cadherin expression wasn’t an independent prognostic factor of local recurrence free survival (LRFS) in patients with LSCC (P = 0.56 and 0.28) respectively. However, the univariate analysis revealed a significant association between them and LRFS (p = 0.003 and 0.000) respectively. Also, the group of high cyclin D1 /low E-cadherin expression had the poorest prognosis, so they might serve as potential predictors of the prognosis of the patients with LSCC. E-cadherin was found to affect the overall survival (OAS) significantly by the univariate analysis (p = 0.01). However, by the multivariate analysis the TNM stage was the only independent prognostic factor of OAS (p < 0.05). Cyclin D1 can be used as an independent prognostic marker of lymph node metastasis in patients with LSCC and can help to identify those patients with clinically negative lymph nodes but with considerable risk for occult metastasis. Detection of cyclin D1 and E-cadherin status in LSCC may contribute to the identification of patients with high risk factors of local recurrence. However, they don’t appear to be better prognostic predictors than other established markers in LSCC.
Literatur
1.
Luke CG, Yeoh E, Roder DM (2008) Exploring trends in laryngeal cancer incidence, mortality and survival: implications for research and cancer control. Asian Pac J Cancer Prev 9(3):397–402PubMed
2.
Freedman LS, Edwards BK, Ries LAG et al (2006) Cancer incidence in four member countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) compared with US SEER. National Cancer Institute. NIH Pub. No. 06–5873. Bethesda, MD. Chapter title; Overview and Summary Data; (1): pp 1–27. Edited by Freedman LS, Edwards BK, Ries LAG, et al
3.
Torrente MC, Rodrigo JP, Haigentz M et al (2011) Human papillomavirus infections in laryngeal cancer. Head Neck 33(4):581–586PubMedCrossRef
4.
Krecicki T, Smigiel R, Fraczek M et al (2004) Studies of the cell cycle regulatory proteins, P16, cyclinD1and retinoblastoma protein in laryngeal carcinoma tissue. J Laryngol Otol 118(9):676–680PubMedCrossRef
5.
Cristóbal E, Arribas B, Tardio J et al (2000) Analysis of the cyclin D1/p16/pRb pathway in parathyroid adenomas. Endocr Pathol 11(3):259–266PubMedCrossRef
6.
vanDiest PJ, Michalides RJAM, Jannink I et al (1997) Cyclin D1 expression in invasive breast cancer: correlations and prognostic value. Am J Pathol 150(2):705–711
7.
Ishikawa T, Furihata M, Ohtsuki Y et al (1998) Cyclin D1 overexpression related to retinoblastoma protein expression as a prognostic marker in human oesophageal squamous cell carcinoma. Br J Cancer 77(1):92–97PubMedCentralPubMedCrossRef
8.
Wangefjord S, Manjer J, Gaber A et al (2011) Cyclin D1 expression in colorectal cancer is a favourable prognostic factor in men but not in women in a prospective, population-based cohort study. Biol Sex Differ 2:10PubMedCentralPubMedCrossRef
9.
Ito Y, Matsuura N, Sakon M et al (1999) Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology 30(1):90–99PubMedCrossRef
10.
Fracchiolla NS, Pruneri G, Pignataro L et al (1997) Molecular and immunohistochemical analysis of the bcl-1/cyclin D1 gene in laryngeal squamous cell carcinomas: correlation of protein expression with lymph node metastases and advanced clinical stage. Cancer 79(6):1114–1121PubMedCrossRef
11.
Do NY, Park SY, Lim SC (2004) The role of E-cadherin/B2-catenin complex and cyclin D1 in head and neck squamous cell carcinoma. Cancer Res Treat 36(1):72–78PubMedCentralPubMedCrossRef
12.
Berx G, Staes K, van Hengel J et al (1995) Cloning and characterization of the human invasion suppressor gene E-cadherin (CDH1). Genomics 26(2):281–289PubMedCrossRef
13.
Kashibuchi K, Tomita K, Schalken JA et al (2006) The prognostic value of E-cadherin, alpha-, beta-, and gamma-catenin in urothelial cancer of the upper urinary tract. Eur Urol 49(5):839–845PubMedCrossRef
14.
Loddo M, Kingsbury SR, Rashid M et al (2009) Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer. Br J Cancer 100(6):959–970PubMedCentralPubMedCrossRef
15.
Barnes L, Eveson JW, Reichart PA et al (2005) World Health Organization classification of tumors: pathology and genetics of tumors of the head and neck. Lyon: IARC. Squamous cell carcinoma in; Hypopharynx, larynx and trachea; (3): p p121. Edited by Cardesa A, Gale N, Nadal A et al
16.
Edge SB, Byrd DR, Compton CC et al (2010) Larynx. In: AJCC cancer staging manual, 7th edn. Springer, New York, pp 57–62
17.
Larizadeh MH, Damghani MA, Tabrizchi H et al (2009) Expression of E-cadherin in squamous cell carcinoma of the larynx and its correlation with clinicopathological features. J Med Sci 9(1):41–45
18.
Leon X, Lopez M, Garcia J et al (2008) Recurrent laryngeal squamous cell carcinoma: rTNM versus composite laryngeal recurrence staging system. Proposal for a modification of the CLRSS to improve patient classification. Head Neck 30(7):939–945PubMedCrossRef
19.
Awada A, Lalami Y (2005) Molecular markers, molecular-targeted therapies and taxanes: how to integrate the progress into clinical research and practice for the management of head and neck cancers. Curr Opin Oncol 17(3):209–211PubMedCrossRef
20.
Zhang Y, Xu Z, Jun-Xi Wang J et al (2012) G1/S-specific cyclin-D1 might be a prognostic biomarker for patients with laryngeal squamous cell carcinoma. Asian Pac J Cancer Prev 13(5):2133–2137PubMedCrossRef
21.
Pignataro L, Sambataro G, Pagani D et al (2005) Clinico-prognostic value of D-type cyclins and p27 in laryngeal cancer patients: a review. Acta Otorhinolaryngol Ital 25(2):75–85PubMedCentralPubMed
22.
Vielba R, Eng JBC, Ispizua A et al (2003) Cyclin D1 as prognostic factors in squamous cell carcinoma of the larynx. Laryngoscope 113(1):167–172PubMedCrossRef
23.
Galera-Ruiz H, Ríos-Moreno MJ, González-Cámpora R (2012) The cadherin-catenin complex in laryngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol 269(4):1183–1188PubMedCentralPubMedCrossRef
24.
Li JJ, Zhang GH, Yang XM et al (2012) Reduced E-cadherin expression is associated with lymph node metastases in laryngeal squamous cell carcinoma. Auris Nasus Larynx 39(2):186–192PubMedCrossRef
25.
Paksoy M, Hardal U, Caglar C (2011) Expression of cathepsin D and E-cadherin in primary laryngeal cancers correlation with neck lymph node involvement. J Cancer Res Clin Oncol 137(9):1371–1377PubMedCentralPubMedCrossRef
26.
Rodrigo JP, Domínguez F, Alvarez C et al (2002) Expression of E-cadherin in squamous cell carcinomas of the supraglottic larynx with correlations to clinicopathological features. Eur J Cancer 38(8):1059–1064PubMedCrossRef
27.
Rodrigo JP, Dominguez F, Suárez V et al (2007) Focal adhesion kinase and E-cadherin as markers for nodal metastasis in laryngeal cancer. Arch Otolaryngol 133(2):145–150CrossRef
28.
Michalides RJAM, van Veelen NMJ, Kristel PMP et al (1997) Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 123(5):497–502PubMedCrossRef
29.
Pignataro L, Capaccio P, Pruneri G et al (1996) P53 and cyclin D1 protein expression in glottic laryngeal squamous cell carcinomas involving the anterior commissure (pT1bN0M0). Int J Oncol 3(9):553–557
30.
Snow GB, Patel P, Leemans CR et al (1992) Management of cervical lymph nodes in patients with head and neck cancer. Eur Arch Otorhinolaryngol 249:187–194PubMedCrossRef
31.
Zou J, Yang H, Chen F et al (2010) Prognostic significance of fascin-1 and E-cadherin expression in laryngeal squamous cell carcinoma. Eur J Cancer Prev 19(1):11–17PubMedCrossRef
32.
Pruneri G, Pignataro L, Valentini S et al (2005) Cyclin D3 immunoreactivity is an independent predictor of survival in laryngeal squamous cell carcinoma. Clin Cancer Res 11(1):242–248PubMed
Metadaten
Titel
Prognostic Significance of Cyclin D1 and E-cadherin Expression in Laryngeal Squamous Cell Carcinoma
verfasst von
Rehab Allah Ahmed
Abd El-Aty Shawky
Rasha Hamdy Hamed
Publikationsdatum
01.07.2014
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 3/2014
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-014-9741-6

Weitere Artikel der Ausgabe 3/2014

Pathology & Oncology Research 3/2014 Zur Ausgabe

Research

Tumor-Associated Macrophages are Correlated with Tamoxifen Resistance in the Postmenopausal Breast Cancer Patients

Research

Clinicopathologic Significance of Sox2, CD44 and CD44v6 Expression in Intrahepatic Cholangiocarcinoma

Research

Transforming Growth Factor-Beta Signaling Leads to uPA/PAI-1 Activation and Metastasis: A Study on Human Breast Cancer Tissues

Research

Altered Expression of Multiple Genes Involved in Retinoic Acid Biosynthesis in Human Colorectal Cancer

Research

HIF-1α Expression Correlates with Cellular Apoptosis, Angiogenesis and Clinical Prognosis in Rectal Carcinoma

Research

Fuzzy Clustering Analysis of Osteosarcoma Related Genes

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise